Atrial Fibrillation Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People of Chinese background who have a type of irregular heartbeat (called non-valvular atrial fibrillation) and have been taking one of these blood-thinning medicines for 6 months or more: apixaban, dabigatran, edoxaban, or rivaroxaban.
- People between 18 and 80 years old.
- People who are able to give their written agreement to take part in the trial.
- People who are already scheduled for a planned medical procedure that requires their blood-thinning medicine to be paused for 48 hours.
Who may not be able to join:
- People who had a blood clot (such as a stroke or bowel blockage from a clot) or a serious bleeding event (such as bleeding in the brain or stomach) while taking their blood-thinning medicine.
- People whose kidneys are not filtering blood well enough, based on a specific medical measurement (confirm with trial site).
- People who are taking a dose of their blood-thinning medicine that does not match what is recommended for their age, weight, and kidney function.
- People who are taking their blood-thinning medicine for a reason other than non-valvular atrial fibrillation, such as a history of a narrowed heart valve, a mechanical heart valve, a clotting disorder, or blood clots in the veins or lungs.
- People who have other health conditions that affect how their blood clots, beyond the use of their blood-thinning medicine — such as certain blood cell disorders, liver congestion, or liver failure affecting clotting.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bonaventure Yiu Ming IP, MB ChB, Chinese University of Hong Kong
Phone: 852-28902002
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Specific coagulation assays; Liquid chromatography-mass spectrometry; Pharmacogenomics
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.